Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
Identifieur interne : 000803 ( Main/Exploration ); précédent : 000802; suivant : 000804Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
Auteurs : Minh Patrick Lê [France] ; Nathan Peiffer-Smadja [France] ; Jeremie Guedj [France] ; Nadège Néant [France] ; France Mentré [France] ; Florence Ader [France] ; Yazdan Yazdanpanah [France] ; Gilles Peytavin [France]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (MeSH), Calendrier d'administration des médicaments (MeSH), Essais cliniques comme sujet (méthodes), Humains (MeSH), Hydroxychloroquine (administration et posologie), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (métabolisme), Pneumopathie virale (traitement médicamenteux).
- MESH :
- administration et posologie : Hydroxychloroquine.
- métabolisme : Infections à coronavirus, Pneumopathie virale.
- méthodes : Essais cliniques comme sujet.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Calendrier d'administration des médicaments, Humains, Pandémies.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), Clinical Trials as Topic (methods), Coronavirus Infections (drug therapy), Coronavirus Infections (metabolism), Drug Administration Schedule (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (metabolism).
- MESH :
- chemical , administration & dosage : Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- methods : Clinical Trials as Topic.
- Betacoronavirus, Drug Administration Schedule, Humans, Pandemics.
Abstract
Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.
DOI: 10.1093/jac/dkaa191
PubMed: 32473020
PubMed Central: PMC7314033
Affiliations:
- France
- Auvergne-Rhône-Alpes, Rhône-Alpes, Île-de-France
- Lyon, Paris
- Université Claude Bernard Lyon 1
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.</title><author><name sortKey="Le, Minh Patrick" sort="Le, Minh Patrick" uniqKey="Le M" first="Minh Patrick" last="Lê">Minh Patrick Lê</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMRS-1144, Université de Paris, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Guedj, Jeremie" sort="Guedj, Jeremie" uniqKey="Guedj J" first="Jeremie" last="Guedj">Jeremie Guedj</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Neant, Nadege" sort="Neant, Nadege" uniqKey="Neant N" first="Nadège" last="Néant">Nadège Néant</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentré">France Mentré</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peytavin, Gilles" sort="Peytavin, Gilles" uniqKey="Peytavin G" first="Gilles" last="Peytavin">Gilles Peytavin</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32473020</idno><idno type="pmid">32473020</idno><idno type="doi">10.1093/jac/dkaa191</idno><idno type="pmc">PMC7314033</idno><idno type="wicri:Area/Main/Corpus">001043</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001043</idno><idno type="wicri:Area/Main/Curation">001043</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001043</idno><idno type="wicri:Area/Main/Exploration">001043</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.</title><author><name sortKey="Le, Minh Patrick" sort="Le, Minh Patrick" uniqKey="Le M" first="Minh Patrick" last="Lê">Minh Patrick Lê</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMRS-1144, Université de Paris, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Guedj, Jeremie" sort="Guedj, Jeremie" uniqKey="Guedj J" first="Jeremie" last="Guedj">Jeremie Guedj</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Neant, Nadege" sort="Neant, Nadege" uniqKey="Neant N" first="Nadège" last="Néant">Nadège Néant</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentré">France Mentré</name><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name><affiliation wicri:level="3"><nlm:affiliation>Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peytavin, Gilles" sort="Peytavin, Gilles" uniqKey="Peytavin G" first="Gilles" last="Peytavin">Gilles Peytavin</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>Clinical Trials as Topic (methods)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (metabolism)</term><term>Drug Administration Schedule (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term><term>Calendrier d'administration des médicaments (MeSH)</term><term>Essais cliniques comme sujet (méthodes)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques comme sujet</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Drug Administration Schedule</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Calendrier d'administration des médicaments</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32473020</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>09</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.</ArticleTitle><Pagination><MedlinePgn>2376-2380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa191</ELocationID><Abstract><AbstractText>Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.</AbstractText><CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lê</LastName><ForeName>Minh Patrick</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peiffer-Smadja</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guedj</LastName><ForeName>Jeremie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Néant</LastName><ForeName>Nadège</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentré</LastName><ForeName>France</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ader</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdanpanah</LastName><ForeName>Yazdan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peytavin</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32473020</ArticleId><ArticleId IdType="pii">5849074</ArticleId><ArticleId IdType="doi">10.1093/jac/dkaa191</ArticleId><ArticleId IdType="pmc">PMC7314033</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Paris</li></settlement><orgName><li>Université Claude Bernard Lyon 1</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Le, Minh Patrick" sort="Le, Minh Patrick" uniqKey="Le M" first="Minh Patrick" last="Lê">Minh Patrick Lê</name></region><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name><name sortKey="Guedj, Jeremie" sort="Guedj, Jeremie" uniqKey="Guedj J" first="Jeremie" last="Guedj">Jeremie Guedj</name><name sortKey="Le, Minh Patrick" sort="Le, Minh Patrick" uniqKey="Le M" first="Minh Patrick" last="Lê">Minh Patrick Lê</name><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentré">France Mentré</name><name sortKey="Neant, Nadege" sort="Neant, Nadege" uniqKey="Neant N" first="Nadège" last="Néant">Nadège Néant</name><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><name sortKey="Peytavin, Gilles" sort="Peytavin, Gilles" uniqKey="Peytavin G" first="Gilles" last="Peytavin">Gilles Peytavin</name><name sortKey="Peytavin, Gilles" sort="Peytavin, Gilles" uniqKey="Peytavin G" first="Gilles" last="Peytavin">Gilles Peytavin</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000803 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000803 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32473020
|texte= Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32473020" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |